8-K Announcements
6Material company update
Apr 1, 2026·SEC
Material company update
Mar 2, 2026·SEC
Material company update
Mar 2, 2026·SEC
Zymeworks Inc.(ZYME)Earnings, Financials & Key Ratios
ZYME•NASDAQ
$27.61
$2.05B mkt cap·Price updated May 6, 2026
AboutZymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, breast, and colorectal cancer; and ZW49, a biparatopic anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Bristol-Myers Squibb company; GlaxoSmithKline Intellectual Property Development Ltd.; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; BeiGene, Ltd.; and Exelixis, Inc. It also has licensing and research collaboration with LEO Pharma A/S to research, develop, and commercialize bispecific antibodies; and Iconic Therapeutics, Inc. Zymeworks Inc. was incorporated in 2003 and is headquartered in Vancouver, Canada.Show more
- Revenue$106M+38.9%
- EBITDA$7.63B+6161.5%
- Net Income-$81M+33.9%
- EPS (Diluted)-1.08+33.3%
- Gross Margin89.81%-10.2%
- EBITDA Margin7202.8%+4464.8%
- Operating Margin-87.34%+51.4%
- Net Margin-76.56%+52.4%
- ROE-26.72%+12.5%
- ROIC-25.86%+21.4%
- Debt/Equity0.07+24.5%
ZYME Key Insights
Zymeworks Inc. (ZYME) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Momentum leader: RS Rating 83 (top 17%)
- ✓Strong 5Y sales CAGR of 22.2%
✗Weaknesses
- ✗Negative free cash flow
- ✗Low quality earnings: Net income not backed by cash flow
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
ZYME Price & Volume
Zymeworks Inc. (ZYME) stock price & volume — 10-year historical chart
Loading chart...
ZYME Growth Metrics
Zymeworks Inc. (ZYME) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years27.06%
5 Years22.16%
3 Years-36.43%
TTM38.87%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM33.88%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM32.92%
Return on Capital
10 Years-32.9%
5 Years-21.87%
3 Years-27.78%
Last Year-27.26%
ZYME Recent Earnings
Zymeworks Inc. (ZYME) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 7/12 qtrs (58%)●Beat Revenue 7/12 qtrs (58%)
Q2 2026Latest
Mar 2, 2026EPS
$0.55
Est $0.35
-57.1%
Revenue
$3M
Est $19M
-86.9%
Q4 2025
Nov 6, 2025EPS
$0.26
Est $0.30
+13.3%
Revenue
$28M
Est $19M
+41.7%
Q3 2025
Aug 7, 2025EPS
$0.03
Est $0.52
+105.8%
Revenue
$49M
Est $26M
+89.3%
Q2 2025
May 8, 2025EPS
$0.30
Est $0.45
+33.3%
Revenue
$27M
Est $18M
+50.4%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Mar 2, 2026 | $0.55vs $0.35-57.1% | $3Mvs $19M-86.9% |
| Q4 2025 | Nov 6, 2025 | $0.26vs $0.30+13.3% | $28Mvs $19M+41.7% |
| Q3 2025 | Aug 7, 2025 | $0.03vs $0.52+105.8% | $49Mvs $26M+89.3% |
| Q2 2025 | May 8, 2025 | $0.30vs $0.45+33.3% | $27Mvs $18M+50.4% |
Based on last 12 quarters of dataView full earnings history →
ZYME Peer Comparison
Zymeworks Inc. (ZYME) competitors in Oncology Therapeutics Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 IMVT | 5.83B | 28.67 | -10.50 | -47.07% | 0.00 | |||
 RCUS | 2.62B | 26.00 | -7.90 | -4.26% | -156.36% | -68.97% | 0.16 | |
 MRUS | 6.83B | 90.00 | -26.87 | -12.38% | -6.54% | -50.62% | 0.02 | |
 AGIO | 1.6B | 26.98 | -3.79 | 48.03% | -6.4% | -34.11% | 0.05 | |
 TPST | 56.36M | 2.02 | -1.35 | -5.68% | 0.80 | |||
 ABBV | 362.56B | 204.98 | 86.49 | 8.57% | 6.91% | 62.15% | ||
 ARVN | 656.24M | 10.26 | -8.02 | -0.3% | -30.77% | -14.25% | 0.02 | |
 BCAB | 5.29M | 4.50 | -0.09 | -81.82% | -29.8% |
Compare ZYME vs Peers
Zymeworks Inc. (ZYME) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
ZYME Income Statement
Zymeworks Inc. (ZYME) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 51.76M | 53.02M | 29.54M | 38.95M | 26.68M | 412.48M | 76.01M | 76.3M | 105.97M |
| Revenue Growth % | 370.18% | 2.43% | -44.28% | 31.84% | -31.5% | 1446.03% | -81.57% | 0.38% | 38.87% |
| Cost of Goods Sold | 41.14M | 56.93M | 117.1M | 170.9M | 0 | 0 | 142.99M | 0 | 10.79M |
| COGS % of Revenue | 79.49% | 107.37% | 396.34% | 438.75% | - | - | 188.11% | - | 10.19% |
| Gross Profit | 10.62M▲ 0% | -3.91M▼ 136.8% | -87.55M▼ 2140.9% | -131.94M▼ 50.7% | 26.68M▲ 120.2% | 412.48M▲ 1446.0% | -66.98M▼ 116.2% | 76.3M▲ 213.9% | 95.17M▲ 24.7% |
| Gross Margin % | 20.51% | -7.37% | -296.34% | -338.75% | 100% | 100% | -88.11% | 100% | 89.81% |
| Gross Profit Growth % | 143.26% | -136.8% | -2140.9% | -50.7% | 120.22% | 1446.03% | -116.24% | 213.93% | 24.73% |
| Operating Expenses | 59.22M | 86.15M | 63.75M | 55.52M | 242.31M | 281.95M | 71.08M | 213.41M | 187.72M |
| OpEx % of Revenue | 114.42% | 162.48% | 215.78% | 142.55% | 908.22% | 68.36% | 93.51% | 279.69% | 177.15% |
| Selling, General & Admin | 18.55M | 29.46M | 62.88M | 55.17M | 42.6M | 73.4M | 70.4M | 61.5M | 50.72M |
| SG&A % of Revenue | 35.84% | 55.56% | 212.82% | 141.65% | 159.67% | 17.79% | 92.62% | 80.6% | 47.86% |
| Research & Development | 41.75M | 56.68M | 118.25M | 171.34M | 199.75M | 208.6M | 143.62M | 134.62M | 137M |
| R&D % of Revenue | 80.66% | 106.91% | 400.23% | 439.9% | 748.7% | 50.57% | 188.94% | 176.43% | 129.29% |
| Other Operating Expenses | -964K | -1.26M | -117.37M | -171M | -39K | -42K | -142.94M | 17.29M | 0 |
| Operating Income | -9M▲ 0% | -33.13M▼ 268.2% | -151.3M▼ 356.7% | -187.47M▼ 23.9% | -215.63M▼ 15.0% | 130.53M▲ 160.5% | -138.05M▼ 205.8% | -137.11M▲ 0.7% | -92.55M▲ 32.5% |
| Operating Margin % | -17.38% | -62.48% | -512.12% | -481.29% | -808.22% | 31.64% | -181.62% | -179.69% | -87.34% |
| Operating Income Growth % | 76.24% | -268.16% | -356.73% | -23.9% | -15.02% | 160.53% | -205.77% | 0.68% | 32.5% |
| EBITDA | -6.26M | -29.5M | -148.99M | -184.11M | -206.05M | 142.53M | -120.75M | -125.92M | 7.63B |
| EBITDA Margin % | -12.09% | -55.63% | -504.3% | -472.68% | -772.3% | 34.55% | -158.85% | -165.02% | 7202.8% |
| EBITDA Growth % | 83.01% | -371.27% | -405.1% | -23.57% | -11.92% | 169.17% | -184.72% | -4.28% | 6161.49% |
| D&A (Non-Cash Add-back) | 2.74M | 3.63M | 2.31M | 3.35M | 9.58M | 12M | 17.3M | 11.19M | 7.72B |
| EBIT | -7.93M | -33.36M | -150.43M | -187.12M | -215.67M | 130.49M | -138.01M | -119.82M | -79.75M |
| Net Interest Income | -397K | 2.47M | 5.88M | 5.7M | 1.97M | 3.6M | 19.7M | 19.94M | 3.53B |
| Interest Income | 743K | 2.64M | 5.88M | 5.7M | 1.97M | 3.6M | 19.7M | 19.94M | 3.53B |
| Interest Expense | 1.14M | 166K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Income/Expense | -964K | -1.02M | 6.45M | 7.34M | 3.27M | 4.71M | 18.81M | 20.5M | 12.79M |
| Pretax Income | -9.96M▲ 0% | -34.38M▼ 245.2% | -144.85M▼ 321.3% | -180.12M▼ 24.3% | -212.36M▼ 17.9% | 135.23M▲ 163.7% | -119.24M▼ 188.2% | -116.61M▲ 2.2% | -79.75M▲ 31.6% |
| Pretax Margin % | -19.25% | -64.85% | -490.3% | -462.43% | -795.95% | 32.79% | -156.87% | -152.82% | -75.26% |
| Income Tax | 444K | 2.17M | 582K | 429K | -516K | 10.89M | -568K | 6.08M | 1.38M |
| Effective Tax Rate % | -4.46% | -6.31% | -0.4% | -0.24% | 0.24% | 8.05% | 0.48% | -5.22% | -1.73% |
| Net Income | -10.41M▲ 0% | -36.56M▼ 251.3% | -145.44M▼ 297.8% | -180.55M▼ 24.1% | -211.84M▼ 17.3% | 124.34M▲ 158.7% | -118.67M▼ 195.4% | -122.69M▼ 3.4% | -81.13M▲ 33.9% |
| Net Margin % | -20.1% | -68.95% | -492.27% | -463.54% | -794.01% | 30.14% | -156.13% | -160.8% | -76.56% |
| Net Income Growth % | 69.22% | -251.3% | -297.85% | -24.14% | -17.33% | 158.69% | -195.44% | -3.39% | 33.88% |
| Net Income (Continuing) | -10.41M | -36.56M | -145.44M | -180.55M | -211.84M | 124.34M | -118.67M | -122.69M | -81.13M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.49▲ 0% | -1.26▼ 157.1% | -3.83▼ 204.0% | -3.58▲ 6.5% | -4.61▼ 28.8% | 1.90▲ 141.2% | -1.72▼ 190.5% | -1.62▲ 5.8% | -1.08▲ 33.3% |
| EPS Growth % | 71.51% | -157.14% | -203.97% | 6.53% | -28.77% | 141.21% | -190.53% | 5.81% | 33.33% |
| EPS (Basic) | -0.49 | -1.26 | -3.83 | -3.58 | -4.06 | 1.91 | -1.72 | -1.62 | -1.08 |
| Diluted Shares Outstanding | 21.32M | 29.09M | 38.02M | 50.38M | 52.13M | 65.25M | 68.86M | 75.88M | 75.34M |
| Basic Shares Outstanding | 21.25M | 29.01M | 37.97M | 50.38M | 52.13M | 65.19M | 68.86M | 75.85M | 75.34M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
ZYME Balance Sheet
Zymeworks Inc. (ZYME) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 92.33M | 204.37M | 311.83M | 455.08M | 288.22M | 544.71M | 412.93M | 300.45M | 233.44M |
| Cash & Short-Term Investments | 87.8M | 200.16M | 298.9M | 426.35M | 252.61M | 492.23M | 374.33M | 225.78M | 228.8M |
| Cash Only | 35.95M | 42.2M | 128.45M | 242.04M | 201.87M | 400.91M | 157.56M | 66.1M | 41.16M |
| Short-Term Investments | 51.85M | 157.96M | 170.45M | 184.32M | 50.74M | 91.32M | 216.77M | 159.67M | 187.64M |
| Accounts Receivable | 2.33M | 358K | 2.19M | 15.29M | 15.61M | 33.4M | 19.48M | 55.81M | 4.64M |
| Days Sales Outstanding | 16.43 | 2.46 | 26.99 | 143.31 | 213.61 | 29.56 | 93.53 | 266.99 | 15.98 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - | - |
| Other Current Assets | 0 | 0 | 0 | 0 | 0 | 19.07M | 19.12M | 18.86M | 0 |
| Total Non-Current Assets | 39.62M | 39.99M | 56.38M | 83.3M | 100.91M | 104.02M | 167.95M | 162.64M | 113.09M |
| Property, Plant & Equipment | 7.18M | 6.48M | 16.5M | 17.61M | 49.77M | 47.65M | 37.54M | 34.32M | 0 |
| Fixed Asset Turnover | 7.21x | 8.18x | 1.79x | 2.21x | 0.54x | 8.66x | 2.02x | 2.22x | - |
| Goodwill | 12.02M | 12.02M | 12.02M | 12.02M | 12.02M | 12.02M | 12.02M | 12.02M | 12.02B |
| Intangible Assets | 19.14M | 20.01M | 23.68M | 22.93M | 21.47M | 26.38M | 25.28M | 4.58M | 1.35B |
| Long-Term Investments | 0 | 0 | 0 | 25.92M | 886K | 886K | 81.93M | 98.43M | 41.79M |
| Other Non-Current Assets | 1.22M | 1.4M | 2.96M | 3.1M | 13.7M | 15.74M | 7.57M | 8.92M | -13.29B |
| Total Assets | 131.96M▲ 0% | 244.36M▲ 85.2% | 368.2M▲ 50.7% | 538.38M▲ 46.2% | 389.13M▼ 27.7% | 648.73M▲ 66.7% | 580.88M▼ 10.5% | 463.09M▼ 20.3% | 346.53M▼ 25.2% |
| Asset Turnover | 0.39x | 0.22x | 0.08x | 0.07x | 0.07x | 0.64x | 0.13x | 0.16x | 0.31x |
| Asset Growth % | 40.39% | 85.19% | 50.68% | 46.22% | -27.72% | 66.71% | -10.46% | -20.28% | -25.17% |
| Total Current Liabilities | 14.66M | 29.99M | 82.55M | 85.67M | 71.85M | 95.63M | 55.76M | 88.29M | 42.32M |
| Accounts Payable | 1.66M | 2.6M | 5.35M | 6.24M | 5.17M | 7.86M | 6.21M | 3.9M | 36.35M |
| Days Payables Outstanding | 14.76 | 16.66 | 16.67 | 13.34 | - | - | 15.86 | - | 1.23K |
| Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3.47M |
| Deferred Revenue (Current) | 7.55M | 3.53M | 0 | 0 | 0 | 2.35M | 3.7M | 25.59M | 0 |
| Other Current Liabilities | 2.04M | 20.63M | 50.59M | 48.74M | 11.1M | 16.01M | 8.68M | 7.49M | 2.5M |
| Current Ratio | 6.30x | 6.82x | 3.78x | 5.31x | 4.01x | 5.70x | 7.41x | 3.40x | 5.52x |
| Quick Ratio | 6.30x | 6.82x | 3.78x | 5.31x | 4.01x | 5.70x | 7.41x | 3.40x | 5.52x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 866K | 33.89M | 39.97M | 42.79M | 68.19M | 60.14M | 60.31M | 36.03M | 35.71M |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 52K | 42K | 5.64M | 5.93M | 31.02M | 24.79M | 22.46M | 15.77M | 14.8M |
| Deferred Tax Liabilities | 0 | 114K | 408K | 1.18M | 1.57M | 1.79M | 3.3M | 4.76M | 6.03M |
| Other Non-Current Liabilities | 814K | 904K | 978K | 2.73M | 2.65M | 2.98M | 1.61M | 895K | 278K |
| Total Liabilities | 15.53M | 63.87M | 122.52M | 128.45M | 140.04M | 155.77M | 116.07M | 124.32M | 78.03M |
| Total Debt | 62K | 57K | 6.93M | 8.64M | 32.33M | 28.11M | 26.72M | 18.51M | 18.27M |
| Net Debt | -35.88M | -42.15M | -121.52M | -233.39M | -169.53M | -372.8M | -130.84M | -47.6M | -22.89M |
| Debt / Equity | 0.00x | - | 0.03x | 0.02x | 0.13x | 0.06x | 0.06x | 0.05x | 0.07x |
| Debt / EBITDA | - | - | - | - | - | 0.20x | - | - | 0.00x |
| Net Debt / EBITDA | - | - | - | - | - | -2.62x | - | - | -0.00x |
| Interest Coverage | -6.96x | -200.99x | - | - | - | - | - | - | - |
| Total Equity | 116.43M▲ 0% | -145.27M▼ 224.8% | 245.68M▲ 269.1% | 409.92M▲ 66.9% | 249.09M▼ 39.2% | 492.96M▲ 97.9% | 464.81M▼ 5.7% | 338.77M▼ 27.1% | 268.5M▼ 20.7% |
| Equity Growth % | 1193.36% | -224.77% | 269.12% | 66.85% | -39.23% | 97.9% | -5.71% | -27.12% | -20.74% |
| Book Value per Share | 5.46 | -4.99 | 6.46 | 8.14 | 4.78 | 7.55 | 6.75 | 4.46 | 3.56 |
| Total Shareholders' Equity | 116.43M | -145.27M | 245.68M | 409.92M | 249.09M | 492.96M | 464.81M | 338.77M | 268.5M |
| Common Stock | 222.99M | 320.07M | 450.21M | 724.22M | 741.15M | 906.76M | 1.01B | 1.02B | 1.11B |
| Retained Earnings | -108.72M | -145.27M | -290.71M | -471.26M | -683.1M | -558.76M | -677.44M | -830.34M | -953.16M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -6.66M | -6.66M | -6.66M | -6.66M | -6.66M | -6.66M | -6.6M | -6.95M | -6.08M |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
ZYME Cash Flow Statement
Zymeworks Inc. (ZYME) cash flow — operating, investing & free cash flow history
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | 219K | 24.18M | -81.85M | -151.4M | -192.45M | 144.11M | -118.3M | -110.04M | -33.01M |
| Operating CF Margin % | 0.42% | 45.6% | -277.05% | -388.7% | -721.33% | 34.94% | -155.64% | -144.22% | -31.15% |
| Operating CF Growth % | 100.62% | 10939.73% | -438.56% | -84.97% | -27.11% | 174.88% | -182.09% | 6.98% | 70.01% |
| Net Income | -10.41M | -36.56M | -145.44M | -180.55M | -211.84M | 124.34M | -118.67M | -122.69M | -81.13M |
| Depreciation & Amortization | 2.74M | 3.63M | 7.33M | 10.28M | 9.58M | 12M | 17.3M | 11.19M | 10.79M |
| Stock-Based Compensation | 3.43M | 13.44M | 49M | 29.12M | 10.76M | 4.01M | 8.1M | 17.79M | 28.03M |
| Deferred Taxes | 15K | -17K | -726K | 266K | -953K | 1.94M | -757K | 691K | 945K |
| Other Non-Cash Items | 2.66M | 3.75M | 1.54M | -364K | -387K | -2.21M | 1.27M | 13.93M | 848K |
| Working Capital Changes | 1.78M | 39.92M | 6.44M | -10.15M | 393K | 4.01M | -25.55M | -30.95M | 7.5M |
| Change in Receivables | 2.41M | -119K | -1.83M | -13.11M | -266K | -17.51M | 13.92M | -36.36M | 51.2M |
| Change in Inventory | 0 | -111K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | -358K | 3.68M | 21.57M | 7.62M | 16.48M | 26.48M | -44.77M | 14.34M | -23.65M |
| Cash from Investing | -30.89M | -109.05M | -25.59M | -43.44M | 144.6M | -53.85M | -207.25M | 38.76M | 26.66M |
| Capital Expenditures | -3.12M | -3.42M | -6.32M | -6.26M | -12.4M | -13.13M | -2.47M | -1.99M | -2.35M |
| CapEx % of Revenue | 6.03% | 6.45% | 21.4% | 16.08% | 46.49% | 3.18% | 3.25% | 2.61% | 2.22% |
| Acquisitions | 0 | 0 | 0 | 1.96M | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - |
| Other Investing | -27.77M | -105.63M | -7.56M | -1.96M | -881K | 40.72M | -1.6M | -1.07M | 0 |
| Cash from Financing | 49.95M | 91.43M | 193.66M | 308.98M | 8.01M | 108.58M | 81.85M | -20.45M | -18.56M |
| Debt Issued (Net) | -7.82M | -11K | -16K | -41K | -17K | -14K | -21K | -14K | 0 |
| Equity Issued (Net) | 55.79M | 90.75M | 188.23M | 300.91M | 0 | 107.53M | 76.09M | -30.05M | -18.38M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -30.05M | -41.7M |
| Other Financing | 1.98M | 690K | 5.45M | 8.11M | 8.03M | 1.06M | 5.77M | 9.61M | -181K |
| Net Change in Cash | 19.51M▲ 0% | 6.26M▼ 67.9% | 86.25M▲ 1278.0% | 113.58M▲ 31.7% | -40.17M▼ 135.4% | 199.04M▲ 595.5% | -243.35M▼ 222.3% | -91.45M▲ 62.4% | -24.95M▲ 72.7% |
| Free Cash Flow | -2.9M▲ 0% | 20.76M▲ 815.3% | -95.73M▼ 561.2% | -157.67M▼ 64.7% | -205.74M▼ 30.5% | 130.98M▲ 163.7% | -122.38M▼ 193.4% | -113.11M▲ 7.6% | -34.53M▲ 69.5% |
| FCF Margin % | -5.61% | 39.15% | -324.03% | -404.79% | -771.12% | 31.76% | -161% | -148.24% | -32.58% |
| FCF Growth % | 92.87% | 815.27% | -561.2% | -64.7% | -30.49% | 163.67% | -193.43% | 7.57% | 69.48% |
| FCF per Share | -0.14 | 0.71 | -2.52 | -3.13 | -3.95 | 2.01 | -1.78 | -1.49 | -0.46 |
| FCF Conversion (FCF/Net Income) | -0.02x | -0.66x | 0.56x | 0.84x | 0.91x | 1.16x | 1.00x | 0.90x | 0.41x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3.18M | 0 |
ZYME Key Ratios
Zymeworks Inc. (ZYME) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -248.22% | -16.59% | - | -289.69% | -55.08% | -64.29% | 33.51% | -24.78% | -30.54% | -26.72% |
| Return on Invested Capital (ROIC) | -1528.42% | -17.41% | - | -91.4% | -93.52% | -126.3% | 98.03% | -45.6% | -32.9% | -25.86% |
| Gross Margin | -222.93% | 20.51% | -7.37% | -296.34% | -338.75% | 100% | 100% | -88.11% | 100% | 89.81% |
| Net Margin | -307.1% | -20.1% | -68.95% | -492.27% | -463.54% | -794.01% | 30.14% | -156.13% | -160.8% | -76.56% |
| Debt / Equity | 0.49x | 0.00x | - | 0.03x | 0.02x | 0.13x | 0.06x | 0.06x | 0.05x | 0.07x |
| Interest Coverage | -39.93x | -6.96x | -200.99x | - | - | - | - | - | - | - |
| FCF Conversion | 1.04x | -0.02x | -0.66x | 0.56x | 0.84x | 0.91x | 1.16x | 1.00x | 0.90x | 0.41x |
| Revenue Growth | 13.96% | 370.18% | 2.43% | -44.28% | 31.84% | -31.5% | 1446.03% | -81.57% | 0.38% | 38.87% |
ZYME SEC Filings & Documents
Zymeworks Inc. (ZYME) SEC filings — annual & quarterly reports (10-K, 10-Q)
ZYME Frequently Asked Questions
Zymeworks Inc. (ZYME) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Zymeworks Inc. (ZYME) reported $106.0M in revenue for fiscal year 2025. This represents a 6245% increase from $1.7M in 2014.
Zymeworks Inc. (ZYME) grew revenue by 38.9% over the past year. This is strong growth.
Zymeworks Inc. (ZYME) reported a net loss of $81.1M for fiscal year 2025.
Dividend & Returns
Zymeworks Inc. (ZYME) has a return on equity (ROE) of -26.7%. Negative ROE indicates the company is unprofitable.
Zymeworks Inc. (ZYME) had negative free cash flow of $34.9M in fiscal year 2025, likely due to heavy capital investments.
Explore More ZYME
Zymeworks Inc. (ZYME) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates